Growth Hormone Treatment in Adults with Adult-Onset Growth Hormone Deficiency Increases Iliac Crest Trabecular Bone Turnover: A 1-Year, Double-Blind, Randomized, Placebo-Controlled Study
Open Access
- 1 February 2000
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 15 (2) , 293-300
Abstract
The effects of growth hormone (GH) substitution on bone metabolism were evaluated by dynamic histomorphometry on iliac crest bone biopsies. Twenty‐nine patients, aged 21–61 years (mean 45.5 years), with adult‐onset GH deficiency (GHD) were randomized to receive subcutaneous injections with GH (2 IU/m2/day = 0.67 mg/m2/day) or placebo for 12 months. Serum insulin‐linke growth factor I (IGF‐I) levels increased 263 ± 98% (mean ± SD) during GH treatment (p < 0.0001). In the GH group, osteoid surface increased during treatment from 11% (3–15%) (median [25–75 percentiles]) to 21% (10–27%) (p = 0.01) and mineralizing surface from 4% (1–8%) to 11% (7–16%) (p = 0.04). Moreover, erosion surface tended to increase in the GH group from 2% (1–3%) to 4% (3–5%) (p = 0.07). The quiescent surface decreased in the GH group from 87% (83–96%) to 74% (68–87%) (p = 0.01). The adjusted appositional rate, mineral apposition rate, bone formation rate, bone erosion rate, mineralization lag time, and osteoid thickness remained unchanged during treatment Erosion depth showed a trend toward increase in the GH group (p = 0.09), whereas wall thickness was unchanged. Bone balance at the remodeling unit level and activation frequency were unchanged. At the tissue level, bone erosion rate increased significantly from 26% (17–36%)/year to 39% (23–72%)/year (p = 0.03). Similarly, the bone formation rate at the tissue level tended to increase, from 24% (15–31%)/year to 36% (17%‐63%)%/year (p = 0.06). Finally, bone balance at the tissue level decreased significantly from 1% (–2–2%)/year to −5% (−13–1%)/year (p = 0.01). No significant difference in change was seen in the cancellous bone volume. We conclude that 12 months of GH substitution therapy increases trabecular bone turnover. Moreover, our data suggest that bone balance at the bone multicellular unit level is not changed to positive. (J Bone Miner Res 2000;15:293–300)Keywords
This publication has 38 references indexed in Scilit:
- Effects of recombinant human growth hormone and insulin-like growth factor-I, with or without 17β-estradiol, on bone and mineral homeostasis of aged ovariectomized ratsJournal of Bone and Mineral Research, 1996
- The influence of growth hormone on cancellous and cortical bone of the vertebral body in aged ratsJournal of Bone and Mineral Research, 1996
- Short-term treatment with growth hormone stimulates osteoblastic and osteoclastic activity in osteopenic postmenopausal women: A dose response studyJournal of Bone and Mineral Research, 1995
- Whole body and regional soft tissue changes in growth hormone deficient adults after one year of growth hormone treatment: a double‐blind, randomized, placebo‐controlled studyClinical Endocrinology, 1995
- Short and long‐term effects of growth hormone treatment on bone turnover and bone mineral content in adult growth hormone‐deficient males*Clinical Endocrinology, 1993
- Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiencyThe Journal of Pediatrics, 1993
- Reconstruction of the formative site in trabecular bone by a new, quick, and easy methodBone, 1992
- Effects of two different regimens of recombinant human growth hormone therapy on the bone mineral density of patients with growth hormone deficiencyThe Journal of Pediatrics, 1991
- Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committeeJournal of Bone and Mineral Research, 1987
- Bone mineral status in growth hormone deficiencyThe Journal of Pediatrics, 1980